- • Featured up ~20-24% premarket near $4.80 on the FDA lifting the ARD-101 clinical hold.
- • A premarket release from the ended Phase 3 HERO trial erased the gap; opened ~$2.99.
- • Sold off all session to close ~$1.39, -64.8% vs $3.95, on ~16.4M shares.
- • Featured on Q3 EPS of $1.33 vs $1.27 consensus and a raised full-year outlook.
- • Spiked to $98.14 intraday, then faded but held the gain.
- • Closed ~$83.39, +5.0% vs $79.42, on ~4.6M shares.
- • Featured on reports SpaceX is targeting 80,000 US cell sites, in talks with Crown Castle.
- • Opened ~$91.02, faded through the session but never tested support.
- • Closed ~$85.97, +9.1% vs $78.83, on ~17.3M shares.
- • Featured on fiscal Q2 revenue of $1.48B vs $1.51B consensus and a cut full-year outlook.
- • Premarket near $77; recovered intraday but stayed red.
- • Closed ~$81.09, -4.9% vs $85.28.
- • WDC: beat-and-raise (revenue $4.381B, +55%) still sold; closed ~$343.67, -3.0% vs $354.19.
- • BE: record Q3 revenue ($1.235B, +138%) and raised guide still sold on ~$181M negative free cash flow.
- • BE closed ~$193.30, -11.2%, on heavy volume of ~35M shares.
Useful?